New! View global litigation for patent families

WO1996002272A3 - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases

Info

Publication number
WO1996002272A3
WO1996002272A3 PCT/EP1995/002885 EP9502885W WO1996002272A3 WO 1996002272 A3 WO1996002272 A3 WO 1996002272A3 EP 9502885 W EP9502885 W EP 9502885W WO 1996002272 A3 WO1996002272 A3 WO 1996002272A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
host
autoimmune
preventing
diseases
protein
Prior art date
Application number
PCT/EP1995/002885
Other languages
French (fr)
Other versions
WO1996002272A2 (en )
Inventor
Erna Moeller
Cecilia Soederberg
Original Assignee
Erna Moeller
Cecilia Soederberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088Varicella-zoster virus, e.g. cytomegalovirus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Autoimmune diseases such as graft versus host disease, are associated with the development of an autoimmune response, such as autoantibodies raised against a host protein carried by an infecting microorganism. The invention provides methods of combatting autoimmune diseases by preventing the organism from infecting the host, by vaccination, by preventing the antibodies from effecting tissue damage, and by preventing the organisms from initiating an immune response in the host. The invention includes modified microorganisms which either lack the host protein or in which the host protein is non-immunogenic.
PCT/EP1995/002885 1994-07-20 1995-07-20 Treatment of autoimmune diseases WO1996002272A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB9414652A GB9414652D0 (en) 1994-07-20 1994-07-20 Method of treatment
GB9414652.9 1994-07-20

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19950927691 EP0773793A1 (en) 1994-07-20 1995-07-20 Treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
WO1996002272A2 true WO1996002272A2 (en) 1996-02-01
WO1996002272A3 true true WO1996002272A3 (en) 1996-03-21

Family

ID=10758627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002885 WO1996002272A3 (en) 1994-07-20 1995-07-20 Treatment of autoimmune diseases

Country Status (3)

Country Link
EP (1) EP0773793A1 (en)
GB (1) GB9414652D0 (en)
WO (1) WO1996002272A3 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334301A1 (en) * 1988-03-21 1989-09-27 Chiron Viagene, Inc. Recombinant retroviruses
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement
US5252603A (en) * 1989-03-15 1993-10-12 Cetus Corporation Immunosuppressive analogues and derivatives of succinylacetone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334301A1 (en) * 1988-03-21 1989-09-27 Chiron Viagene, Inc. Recombinant retroviruses
US5252603A (en) * 1989-03-15 1993-10-12 Cetus Corporation Immunosuppressive analogues and derivatives of succinylacetone
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOHAN NEYTS ET AL.: "Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate", VIROLOGY, vol. 189, no. 1, pages 48 - 58 *
M. O. WESTENDORP ET AL.: "Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120", NATURE, vol. 375, pages 497 - 500 *
PENTTI UKKONEN: "Production of polyclonal antisera against cytomegalovirus and varicella-zoster virus by use of affinity-purified viral antigens", APMIS (ACTA PATHOL MICROBIOL IMMUNOL SCAND), vol. 97, no. 3, pages 267 - 273 *
TROND FLAEGSTAD ET AL.: "Inoculation with BK virus may break immunological tolerance to histone and DNA antigens", PROC. NATL. ACAD. SCI. USA, vol. 85, no. 21, pages 8171 - 8175 *

Also Published As

Publication number Publication date Type
EP0773793A1 (en) 1997-05-21 application
GB9414652D0 (en) 1994-09-07 grant
WO1996002272A2 (en) 1996-02-01 application

Similar Documents

Publication Publication Date Title
WO1998055495B1 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2003029401A8 (en) Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
WO1997048370A3 (en) Vaccines comprising synthetic genes
WO2001038523A1 (en) A novel polypeptide, a human deafness-related gene 14 and the polynucleotide encoding the polypeptide
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2002021141A3 (en) Methods and compositions for diseases associated with amyloidosis
WO1997021807A1 (en) Novel dnas, novel polypeptides and novel antibodies
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO1999041383A8 (en) Antigen library immunization
WO2001046252A1 (en) A novel polypeptide - human diacylglycerol protein kinase subunit 9 and a polynucleotide encoding the same
DE20207502U1 (en) Photoprotected starter culture for microbiological treatment of water, soil, sediments and/or sludges, comprises live chemolithoautotrophic bacteria immobilized in a matrix coated with pigments and/or adsorbents
WO2001062794A3 (en) 18607, a human calcium channel
WO2003083041A8 (en) Cripto-specific antibodies
RU2221809C2 (en) Method for preparing natural humanized antibody
WO1998029534A1 (en) Method for activating human antigen presenting cells, activated human antigen presenting cells, and use of the same
WO2000056360A3 (en) Vaccine against antigens from bacteriae
JPH0211523A (en) Immunoadsorbent for remedy of malignant tumor, etc., and remedying method using the same agent
WO2002000822A2 (en) A NOVEL POLYPEPTIDE, A HUMAIN PROTEIN SYNTHESIS INITIATION FACTOR SUB-UNIT 2 β 16.5 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE
CA2369292A1 (en) Method of modulating the activity of functional immune molecules
RU2226401C2 (en) Methods for detection of inductors and inhibitors of proteolytic antibodies, compositions based on thereof and their application
EP0332424A3 (en) Chimeric antibodies directed against human carcinoembryonic antigen
WO1996021465A3 (en) Immunogenic conjugate molecules
WO1999033977A1 (en) Tumor antigen protein, gene thereof, and utilization thereof
WO1998009990A1 (en) Fungal antigens and process for producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995927691

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: US

Ref document number: 1997 776012

Date of ref document: 19970314

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995927691

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1995927691

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995927691

Country of ref document: EP